May 14, 1992—(Washington, DC) The Competitive Enterprise Institute today charged that FDA’s delay in approving Interleukin-2 may have cost as many as 3500 lives. IL-2 was finally approved last week as the only known therapy for metastic renal cell carcinoma, a fatal form of kidney cancer. Its application had been on file with the agency for three and a half years, since November 1988. During that time, it was approved in France, Demark, and seven other European countries.
Thursday, May 14, 1992
News Releases